Citation only
via Europe PMC
NAD<sup>+</sup> signaling in Parkinson's disease: molecular mechanisms and therapeutic perspectives.
Frontiers in neurology · 2026
Genomic instability
Epigenetic alterations
Loss of proteostasis
Mitochondrial dysfunction
Altered intercellular communication
Chronic inflammation
Disabled macroautophagy
Human
Review
Abstract
Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder worldwide, characterized by the progressive loss of dopaminergic neurons in the substantia nigra, accumulation of α-synuclein (α-syn), mitochondrial dysfunction(definition), and neuroinflammation. Nicotinamide adenine dinucleotide (NAD<sup>+</sup>), a crucial coenzyme involved in cellular energy metabolism, DNA repair, and epigenetic regulation, declines with aging and is markedly reduced in the brains of patients with PD. Emerging evidence suggests that supplementation with NAD<sup>+</sup> precursors, including nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), exerts neuroprotective effects through multiple mechanisms, such as activation of the mitochondrial unfolded protein response (UPR∧mt), enhancement of autophagy(definition), and suppression of excessive poly(ADP-ribose) polymerase 1 (PARP1) activation. This review summarizes the central role of NAD<sup>+</sup> dysregulation in the pathogenesis of PD, with particular emphasis on the interplay between NAD<sup>+</sup> depletion, mitochondrial quality control, proteostasis(definition), and neuroinflammation. Furthermore, we discuss recent advances in NAD<sup>+</sup>-boosting strategies in PD models and clinical studies, highlighting their potential therapeutic implications for PD intervention.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.3389/fneur.2026.1943801
- Canonical
- link ↗
- Fetched
- 2026-10-20 MST
Cite this
APA
T, W., X, Z., & X., C. (2026). NAD<sup>+</sup> signaling in Parkinson's disease: molecular mechanisms and therapeutic perspectives. <em>Frontiers in neurology</em>. https://doi.org/10.3389/fneur.2026.1943801
Vancouver
T W, X Z, X. C. NAD<sup>+</sup> signaling in Parkinson's disease: molecular mechanisms and therapeutic perspectives. Frontiers in neurology. 2026. doi:10.3389/fneur.2026.1943801.
BibTeX
@article{wang2026NADlts,
title = {NAD<sup>+</sup> signaling in Parkinson's disease: molecular mechanisms and therapeutic perspectives.},
author = {Wang T and Zhou X and Chen X.},
journal = {Frontiers in neurology},
year = {2026},
doi = {10.3389/fneur.2026.1943801},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in Neurology 2026
Open access · CC-BY
NAD+ signaling in Parkinson's disease: molecular mechanisms and therapeutic perspectives
Alzheimer's & dementia : the journal of the Alzheimer's Association 2026
Open access · OA
NAD<sup>+</sup>‒circadian rhythm coupling in dementia.
PubMed 2016
Preprint
The pathophysiological importance and therapeutic potential of NAD' biosynthesis and mitochondrial sirtuin SIRT3 in age-associated diseases.
International journal of molecular sciences 2025
Open access · OA
Preventive and Protective Effects of Nicotinamide Adenine Dinucleotide Boosters in Aging and Retinal Diseases.
Current Opinion in Cardiology 2026
Citation only
Role of nicotinamide adenine dinucleotide in cardiovascular disease
Current opinion in cardiology 2026
Citation only